Gleevec Inhibits Cancer-Causing Kinase BCR-ABL

This is part of: Medicine in the Genomic Era


The drug Gleevec binds to and inactivates BCR-ABL, a mutant kinase that causes chronic myeloid leukemia. 

(Duration: 03 min 31 sec)
Launch This Resource
33 other people found this useful

By downloading, you agree to the permissions to use this file.